GenPharm's time to sell

GenPharm's time to sell

Last week's announcement that Medarex Inc. will acquire GenPharm International Inc., for up to $65 million in MEDX common stock, put an upbeat wrap on the GenPharm story.

After completing both a $57 million licensing agreement with Centocor Inc. (CNTO, Malvern, Penn.) for its HuMab mouse technology and settling its lengthy altercation with Cell Genesys Inc. (CEGE,

Read the full 605 word article

How to gain access

Continue reading with a
two-week free trial.